Category: InVivo Therapeutics Corp.
Massachusetts-based InVivo Therapeutics awaits final consent after sending new study protocols to FDA regulators and the 6 sites participating in the company's revamped spinal scaffold clinical trial.
InVivo sets off to launch its 1st investigational clinical trial after landing FDA investigational device exemption for its degradable polymer scaffold for treating spinal cord injury.
InVivo Therapeutics (OTC:NVIV) landed conditional approval from the FDA to change its protocols for its 1st clinical trial, testing its degradable polymer scaffold in treating spinal cord injury.
InVivo Therapeutics' new CEO Mark Perrin comes from a background in biotech consulting and leadership.
InVivo Therapeutics (OTC:NVIV) named Mark Perrin as its new CEO, handing him the keys to the corner office effective January 6.
InVivo Therapeutics taps its 3rd CFO since August, naming Steven McAllister to replace interim CFO Gregory Perry.
InVivo Therapeutics (OTC:NVIV) is on its 3rd financial chief since August, saying it named Steven McAllister to replace interim CFO Gregory Perry.
Perry stepped down effective Dec. 30 to join an unnamed biotechnology company as its CFO, according to a press release.
Imaging3 names Dane Medley as its new CEO, replacing the outgoing Dean James in the corner office.
Imaging3 (OTC:IMGG) said Dane Medley will replace Dean James as chairman & CEO.
Medley's résumé includes time with Xerox (NYSE:XRX) and Sharp Electronics. Medley also started 360 Dynamic Technology, a privately owned startup that provides sales and service for office products/technology.
Veran Medical Technologies appoints former Stryker CFO Curt Hartman as a member of its board of directors.
Veran Medical Technologies said it has brought in former Stryker (NYSE:SYK) CFO Curt Hartman to join its board of directors.
Shares of InVivo Therapeutics gain more than 50% by the end of the day Friday after the company announces that it's ready to set aside its hydrogel product development to focus on an upcoming clinical trial of its degradable spinal scaffold.